BofA raised the firm’s price target on Hims & Hers (HIMS) to $30 from $25 and keeps a Neutral rating on the shares. Amazon’s (AMZN) new offering in the GLP-1 market appears well suited for long-term GLP-1 subscribers that may opt to minimize ongoing costs, says the analyst, who anticipates it could further pressure Hims’ GLP-1 revenue in 2026 and beyond. The firm cites a raised multiple to reflect peptide optionality and peer multiple expansion, offset by yesterday morning’s Amazon news, for its news Hims target.
Claim 55% Off TipRanks
Trade AMZN with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Amazon (AMZN) Steps Up Weight Loss Push, Knocks HIMS Stock Off the Scale
- Mixed options sentiment in Hims and Hers Health with shares down 4.05%
- Amazon on-demand option not a replacement for platforms like Hims, says Citi
- Amazon One Medical introduces weight management program
- Bullish flow in Hims and Hers Health with shares up 8.9%